Table 1.
Clinical and laboratory characteristics of the SLE patients studied
| Case | Current treatment | WBC (×109/L) | Hb (g/dL) | Plt (×109/L) | Lym (×109/L) | Anti-dsDNA | Serum C3 | Serum C4 | 24-hour UP | SLE-DAI |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HCQ 200 mg/d | 3.8 | 16.3 | 23 | 1.3 | <5 | 54 | 13 | 0.24 | 3 |
| 2 | Pred 5 mg/d, HCQ 200 mg/d | 2.04 | 8.6 | 352 | 1.04 | 18 | 80 | 15 | NA | 1 |
| 3 | Pred 12.5 mg/d, MMF 3 mg/d | 10.55 | 9.2 | 281 | 0.45 | 34 | 72 | 24 | 6.57 | 6 |
| 4 | HCQ 300 mg/d | 2.38 | 12.1 | 149 | 0.64 | 127 | 29 | 7.1 | <0.06 | 16 |
| 5 | Pre 15 mg/d, HCQ 200 mg/d, Aza 100 mg/d | 0.8 | 8.9 | 67 | .3 | 19 | 94 | 19 | 0.18 | 6 |
| 6 | Pred 20 mg/d, HCQ 400 mg/d | 1.93 | 11.5 | 131 | 0.49 | 54 | 36 | 2.9 | NA | 15 |
| 7 | Pred 7.5 mg/d, Aza 50 mg/d, MMF 1 mg/d | 2.3 | 9.0 | 70 | 0.2 | 150 | 27 | 9.9 | 0.26 | 15 |
| 8 | Pred 20 mg/d | 4.9 | 10.4 | 207 | 1.4 | 9 | 67 | 13 | NA | 6 |
| 9 | HCQ 200 mg/d | 2.06 | 7.4 | 94 | 0.82 | 85 | 31 | 5.3 | 3.63 | 13 |
| 10 | Pred 12.5 mg/d MMF 3 g/d | 6.0 | 12.0 | 74 | 0.6 | 45 | 58 | 27 | 0.11 | 15 |
| 11 | Pred 50 mg/d | 3.54 | 9.4 | 47 | 0.9 | 29 | 101 | 34 | NA | 2 |
| 12 | Pred 15 mg/d, HCQ 200 mg/d, Aza 100 mg/d | 5.21 | 11.6 | 31 | 0.25 | 12 | 109 | 23 | NA | 1 |
| 13 | HCQ 300 mg/d | 4.1 | 9.5 | 92 | 1.2 | >450 | 26 | 3.7 | 2.4 | 14 |
F, female; Pred, prednisolone;HCQ, hydroxychloroquine;Aza, azathioprine;MMF, mycophenolate mofetil;Hb, hemoglobin; WBC, white blood cell count [NR 4.1-10.9 × 109/L]; Plt, platelet count [NR 140-450 × 109/L]; Lym, lymphocyte count [NR 20-50% of WBCs]; SLEDAI, systemic lupus erythematosus disease activity index.